The generics industry has a big problem: companies are providing drugs cheaper than ever, thanks in part to the limited number of wholesalers that distribute their products. But consumers are not seeing as much of those savings, mainly due to a shift in approach by pharmacy benefit managers toward formularies that value product rebates instead of the cost of the pills.
PBMs and other middleman “took $20bn out from our industry over the last six, seven years,” Amneal Pharmaceuticals, Inc....







